|
US6149909A
(en)
|
1995-06-23 |
2000-11-21 |
Women's And Children's Hospital |
Synthetic α-L-iduronidase and genetic sequences encoding same
|
|
WO1993010244A1
(en)
|
1991-11-14 |
1993-05-27 |
Women's And Children's Hospital |
Synthetic alpha-l-iduronidase and genetic sequences encoding same
|
|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
JP2001500015A
(ja)
|
1996-09-06 |
2001-01-09 |
トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
|
|
WO1999058691A2
(en)
|
1998-05-13 |
1999-11-18 |
Harbor-Ucla |
Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
|
|
EP2369002A1
(en)
|
1999-08-09 |
2011-09-28 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
|
|
US6426208B1
(en)
|
1999-11-12 |
2002-07-30 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
|
|
RU2196988C2
(ru)
|
2000-04-19 |
2003-01-20 |
Государственный новосибирский областной клинический диагностический центр |
Способ диагностики мукополисахаридозов
|
|
AU2001267337A1
(en)
|
2000-06-30 |
2002-01-14 |
Maxygen Aps |
Peptide extended glycosylated polypeptides
|
|
SG10202108118RA
(en)
|
2001-11-13 |
2021-08-30 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
ES2975413T3
(es)
|
2001-12-17 |
2024-07-05 |
Univ Pennsylvania |
Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas
|
|
AU2003302724A1
(en)
|
2002-08-13 |
2004-07-09 |
Mcivor, Scott, R. |
Methods of using vectors to treat metabolic disorders
|
|
US7155804B2
(en)
|
2003-09-17 |
2007-01-02 |
Moog Inc. |
Method of forming an electric motor
|
|
HUE054805T2
(hu)
|
2003-09-30 |
2021-09-28 |
Univ Pennsylvania |
Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
|
|
EP3085389A1
(en)
|
2005-04-07 |
2016-10-26 |
The Trustees Of The University Of Pennsylvania |
Method of increasing the function of an aav vector
|
|
WO2006132118A1
(ja)
|
2005-06-09 |
2006-12-14 |
Matsushita Electric Industrial Co., Ltd. |
振幅誤差補償装置及び直交度誤差補償装置
|
|
WO2007120542A2
(en)
|
2006-03-30 |
2007-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid library and aav capsid proteins
|
|
US20090062144A1
(en)
|
2007-04-03 |
2009-03-05 |
Nancy Lan Guo |
Gene signature for prognosis and diagnosis of lung cancer
|
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
|
BR112012010755A2
(pt)
|
2009-11-05 |
2015-09-22 |
Proyecto Biomedicina Cima Sl |
constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
|
|
KR20130040844A
(ko)
|
2010-03-29 |
2013-04-24 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
약학적으로 유발된 전이유전자 제거 시스템
|
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
EP2394667A1
(en)
|
2010-06-10 |
2011-12-14 |
Laboratorios Del Dr. Esteve, S.A. |
Vectors and sequences for the treatment of diseases
|
|
SG10202007803QA
(en)
|
2011-02-17 |
2020-09-29 |
Univ Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
|
CN107012171B
(zh)
|
2011-04-22 |
2021-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
CA2875618C
(en)
|
2012-07-11 |
2021-04-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
WO2014125647A1
(ja)
|
2013-02-18 |
2014-08-21 |
富士通オプティカルコンポーネンツ株式会社 |
光受信装置
|
|
JP6591956B2
(ja)
|
2013-03-15 |
2019-10-16 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｍｐｓ１を治療するための組成物および方法
|
|
KR20160010526A
(ko)
|
2013-05-15 |
2016-01-27 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
|
|
CA2915296A1
(en)
|
2013-06-11 |
2015-02-26 |
Portage Pharmaceuticals Ltd. |
Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
AU2015320694B2
(en)
|
2014-09-24 |
2021-11-11 |
City Of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
WO2016055437A1
(en)
|
2014-10-06 |
2016-04-14 |
Arthrogen B.V. |
Aav-based gene therapy
|
|
CA2986252A1
(en)
*
|
2015-05-15 |
2016-11-24 |
Regents Of The University Of Minnesota |
Adeno-associated virus vector for delivery of iduronate-2-sulfatase to the central nervous system
|
|
US10604747B2
(en)
|
2015-08-06 |
2020-03-31 |
Academia Sinica |
Engineered enzyme for enzyme replacement therapy
|
|
US12221615B2
(en)
*
|
2015-08-06 |
2025-02-11 |
The Trustees Of The University Of Pennsylvania |
GLP-1 and use thereof in compositions for treating metabolic diseases
|
|
WO2017040254A1
(en)
*
|
2015-08-28 |
2017-03-09 |
Laufer Wind Group Llc |
Mitigation of small unmanned aircraft systems threats
|
|
CA2995733A1
(en)
*
|
2015-08-31 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Aav-epo for treating companion animals
|
|
SG11201803218PA
(en)
*
|
2015-10-23 |
2018-05-30 |
Univ Iowa Res Found |
Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
|
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
AU2017207818B2
(en)
|
2016-01-15 |
2024-03-28 |
Regents Of The University Of Minnesota |
Methods and compositions for the treatment of neurologic disease
|
|
AU2017215211C1
(en)
*
|
2016-02-03 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
IL266639B2
(en)
|
2016-11-15 |
2024-06-01 |
Univ Minnesota |
Method for improving neurological function in mpsi and mpsii and other neurological disorders
|
|
MA47436A
(fr)
|
2017-01-31 |
2019-12-11 |
Regenxbio Inc |
Traitement de la mucopolysaccharidose i avec une alpha-l-iduronidase glycosylée entièrement humaine (idua)
|
|
EP3676385A1
(en)
*
|
2017-07-06 |
2020-07-08 |
The Trustees of The University of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
IL280198B2
(en)
|
2018-07-18 |
2026-01-01 |
Regenxbio Inc |
Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
|
|
EP4093428A1
(en)
|
2020-01-22 |
2022-11-30 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
|
WO2022170082A1
(en)
|
2021-02-05 |
2022-08-11 |
Regents Of The University Of Minnesota |
Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
|